Applied Pharmaceutical Science receives FDA Fast Track Designation for APS03118 for the treatment of metastatic NSCLC previously-treated with a selective RET inhibitor
BEIJING and PHILADELPHIA, Feb. 21, 2022, Applied Pharmaceutical Science, Inc. announced that APS03118, a next-generation selective RET inhibitor, has recently been granted Fast Track Designation by U.S. Food and Drug Administration (FDA) for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NS...…